Cell-based Products

Overview

     HCT/Ps are defined as; “articles containing human cells or tissues that are intended for implantation, transplantation,

infusion, or transfer into a human recipient” by Food and Drug Administration (FDA) and include:

  •   Musculoskeletal tissue and skin
  •   Ocular tissue
  •   Cellular therapies
  •   Hematopoietic stem/progenitor cells
  •   Therapeutic cells (DLI)
  •   Somatic cells (regardless of source)
  •   Reproductive tissue
  •   Combination tissue/device, tissue/drug
  •   Human heart valve allografts
  •   Human Dura mater

Regenerative medicine and (stem) cell therapy is a group of new techniques, or technologies, that rely on replacing diseased or dysfunctional cells with healthy, functioning ones. It also allows scientists to repair damaged cell, tissue and organ. Several disorders are candidate for cellular therapy for instance; Cancers, Diabetes Mellitus, Neurological disorders, Cardiovascular, Autoimmune, Musculoskeletal diseases, Rheumatoid arthritis, etc. Various (stem) cell types have been evaluated for the mentioned applications in basic, experimental, and also clinical trial researches (e.g. mesenchymal stem cell, hematopoietic stem cell, embryonic stem cell, and etc.).

Considering safety concerns regarding regenerative medicine and cellular therapy, HCTPs has been divided into two groups by FDA:

Lower risk- Autologous or family related donors and minimally manipulated and homologous use (GTP compliance is enough for manufacturing this type of products)

Higher risk- Allogeneic unrelated donors and/or more than minimally manipulated and/or non-homologous use (both of GTP and GMP compliance are needed)

GLP- Good Laboratory Practice

GTP- Good Tissue Practice

GMP- Good Manufacturing Practice

GCP- Good Clinical Practice

Objective

This course is established upon the scientific experience and expertise of professionals to provide trainees with valuable skills and experience in this area of science. It is expected to cover suitable issues regarding regenerative medicine and cellular therapy for trainees and their Institutes.

 

Methodology

     The course will provide participants with the knowledge, skills, and hand-on technical expertise necessary to face the challenges of manufacturing HCTPs for basic research or clinical trials. It consists of HCTPs manufacturing standards and guidelines, theoretical knowledge and also practical skills in the field of regenerative medicine. It is to be taught in two modules:

  Theoretical modules (on-line training)

o   Basic cell culture techniques

o   Aseptic techniques and working in controlled environment

o   Cell manufacturing for clinical applications

o   Pre-clinical studies and clinical trial design

These modules include different sub-topics as below,

a.       Basic physiology of cells, tissues  and organs

b.       Current status of (stem) cell and tissue engineering research

c.       Translational sciences in regenerative medicine

d.       Animal modeling and preclinical animal studies

e.       Regenerative medicine and therapeutic potential of cell and tissue products

f.        Cell and tissue manufacturing methodology

g.       Basic principles of cell and tissue banking

h.       International standards and guidelines

i.         Safety concerns

j.         Ethical and legal issues

k.       Quality management systems

l.         Differences between clinical and non-clinical manufacturing of HCTPs

m.    GLP, GTP, and GMP complaint HCTPs

n.       Risk management related to HCTPs

o.       Clinical trial design (GCP) in regenerative medicine

p.       Current state and future perspective of regenerative and HCTPs-based therapy

q.       Different sources of stem cells for research and clinical application

r.        Extra-embryonic tissue derived (stem) cells (Dr. Ornella Parolini).

ü  Placental derived stem cells and their application

ü  Epithelial and mesenchymal (stem) cells from the amniotic membrane

 

  Practical training

o   Essentials of practice in fully equipped GMP facility (clean room)

o   Stem cell manufacturing techniques

  Bone marrow derived mesenchymal stem cell

  Adipose tissue derived stem cells  

  Extra-embryonic tissue derived (stem) cells as a novel source (Dr. Ornella Parolini)

  Placental derived stem cells

  Amnion derived epithelial and mesenchymal stem cells

o   Magnetic cell sorting

o   Stem cell freezing and banking

o   Working with equipments and instruments in these facilities

o   Environmental control, documentation

 

Who can attend?

The course is intended to train biomedical students (B.Sc., M.S., and Ph.D. students) and professionals who are working in the field of (stem) cell research and therapy such as:

  Cell culture staff

  Tissue Bankers

  Quality control staff

  Other professionals from various relevant background who are seeking such courses

 

Course duration

     The course lasts 1year and contains theoretical modules (web-based) and 3 Weeks workshop (in-site training)

 

Application requirements

        The applicants are requested to submit TUMS online application form to apply for this position.

         5’000 $ payment

The language of instruction for this course is English.

TUMS international students will be given the opportunity to use our international dormitories located close to campus in Tehran.

For more information please read TUMS admission criteria and guidelines.

 

 


 

Organizer: Office of Vice-Chancellor for Global Strategies and International Affairs, Tehran University of Medical Sciences (TUMS)

 

Conducted by: Brain and Spinal Injury Research Center affiliated to TUMS (Clinical grade stem cell manufacturing facilities)

 

Course directors:

 

Dr. Babak ArjmandM.D., M.Phil, Ph.D., Managing Director of Clinical and GMP grade cell and tissue manufacturing facilities, Brain and Spinal Injury Research Center, Tehran University of Medical Sciences, Tehran, Iran

 

Dr. Hamidreza AghayanM.D., M.Phil, Ph.D., Medical Director of Clinical and GMP grade cell and tissue manufacturing facilities, Brain and Spinal Injury Research Center, Tehran University of Medical Sciences, Tehran, Iran

 

Visiting professor:

 

 Dr. Ornella Parolini, Regenerative Medicine Research Center, Fondazione Poliambulanza-Instituto Ospelaliero, Brescia, Italy

 

Advisory board:  

 

Dr Stephen Strom, Ph.D., Professor, Cell Transplantation and Regenerative   Medicine, Department of Laboratory Medicine, Division of Pathology, Karolinska Institutet, Stockholm, Sweden

 

Dr Ahmadreza Dehpour, Ph.D., Professor, Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

 

Dr Masoud Soleimani, Ph.D., Associate Professor, Department of Hematology and Blood Banking, Tarbiat Modares University, Tehran, Iran

 

Dr Mohammadtaghi Joqhataei, Ph.D., Professor, Cellular and Molecular Research Center, Iran University of Medical Sciences, Tehran, Iran

 

Dr Gholamreza Pourmand, M.D., Professor, Urology Research Center, Tehran University of Medical Sciences, Tehran, Iran

 

Dr Ali Jafarian, M.D., Associate Professor, Hepatobiliary Surgery & Liver Transplantation Division, Department of General Surgery, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran

 

 

Dr Mohsen Nasiri-toosi, Associate Professor, Department of Gastroenterology, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran

 

 

Last Update At : 11 June 2019
visits:318